stockportfolio.pro
Stocks / RGEN vs TGTX
RGEN vs TGTX
Repligen Corporation and TG Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Repligen Corporation (RGEN) | TG Therapeutics, Inc. (TGTX) | |
|---|---|---|
| Market cap | $7.4B | $7.1B |
| Revenue (latest FY) | $738.26M | $616.29M |
| Net income (latest FY) | $48.89M | $447.18M |
| Revenue growth (5y CAGR) | 15.0% | 426.7% |
| Net margin | 6.6% | 72.6% |
| Return on equity | 2.3% | 69.0% |
| P/E ratio | 144.0 | 16.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RGEN — free Open TGTX — freeFrequently asked questions
Which is bigger, RGEN or TGTX?
Repligen Corporation is larger by market capitalization — $7.4B versus $7.1B.
Which grows faster, RGEN or TGTX?
Over the last five fiscal years, TG Therapeutics, Inc. grew revenue faster — 426.7%/yr versus 15.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.